Sign In
Buy CLPBF
$57.28
-2.41 (-4.03%)
At Close: Jun 02, 2026
Coloplast: Went 'BUY' A Bit Early
10:37am, Saturday, 16'th May 2026
Coloplast is rebased to a 20x P/E with a new price target of 490 DKK, reflecting a more realistic valuation post-premiumization. Recent setbacks—the Kerecis acquisition write-down, product recalls,
Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript
12:10pm, Tuesday, 12'th May 2026
Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript
Coloplast: The Market Is Throwing Away A High-Quality Compounder
07:41am, Tuesday, 17'th Mar 2026
Coloplast is now a clear Buy, trading nearly 60% below its all-time high and at historically low valuation multiples. CLPBF's wide economic moat, underpinned by patents and high switching costs, suppo
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
02:25pm, Wednesday, 11'th Mar 2026
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
05:48pm, Sunday, 08'th Mar 2026
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast appoints Gavin Wood as new CEO
01:52pm, Wednesday, 04'th Mar 2026
Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief
Coloplast A/S - Updated Financial Calendar 2025-26
09:36am, Wednesday, 11'th Feb 2026
Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
03:04pm, Friday, 06'th Feb 2026
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S - Interim Financial Report, Q1 2025/26
09:46am, Friday, 06'th Feb 2026
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew
Coloplast A/S - Interim Financial Report, Q1 2025/26
01:30am, Friday, 06'th Feb 2026
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0
Coloplast announces changes to Executive Leadership Team
09:00am, Thursday, 18'th Dec 2025
Today, Coloplast is announcing changes to the company's Executive Leadership Team (ELT). The changes relate to the company's Interventional Urology business as well as the global People & Culture func
Coloplast A/S (CLPBY) Shareholder/Analyst Call Transcript
04:58pm, Thursday, 04'th Dec 2025
Coloplast A/S (CLPBY) Shareholder/Analyst Call Transcript
Coloplast A/S - Decisions at the Annual General Meeting 2025
11:50am, Thursday, 04'th Dec 2025
Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved. Distribution of y
Coloplast A/S (CLPBY) Q4 2025 Earnings Call Transcript
08:46am, Tuesday, 04'th Nov 2025
Coloplast A/S (OTCPK:CLPBY) Q4 2025 Earnings Call November 4, 2025 5:00 AM EST Company Participants Lars Rasmussen Anders Lonning-Skovgaard - Executive VP & CFO Conference Call Participants Hassan Al-
After A 50% Decline, Coloplast Might Finally Be Worth Buying
05:40am, Wednesday, 29'th Oct 2025
Coloplast is now rated a cautious 'Buy,' as its valuation has become more reasonable after a significant price correction. Coloplast continues to deliver solid organic growth, boasts a wide economic m
